1. The Role of Genetic Markers in the Management of Prostate Cancer
Atish D. Choudhury, Rosalind Eeles, Stephen J. Freedland, William B. Isaacs, Mark M. Pomerantz, Jack A. Schalken, Teuvo L.J. Tammela, Tapio Visakorpi 
European Urology 
Volume 62, Issue 4, Pages (October 2012)
DOI: /j.eururo
Copyright © Terms and Conditions

2. Fig. 1
A sampling of genetic markers proposed to help guide clinical decision making for assessment of risk of developing prostate cancer, and for screening, prognosis, and prediction of response to therapy. AR=androgren receptor; BRAF=v-raf murine sarcoma viral oncogene homolog B1; BRCA2=breast cancer 2, early onset; CCP=cell cycle progression; FISH=fluorescent in situ hybridization; Her2/neu=human epidermal growth factor receptor 2; HNF1B=HNF1 homeobox B; HOXB13=homeobox B13; IHC=immunohistochemistry; KLK2-KLK3=kallikrein-related peptidase 2 and 3; MSMB=β-microseminoprotein; miRNA=microRNA; MYC=v-myc myelocytomatosis viral oncogene homolog (avian); PCA3=prostate cancer antigen 3; phospho-Src=phosphorylated v-src sarcoma (Schmidt-Ruppin A-2) viral oncogene homolog (avian); PSA=prostate-specific antigen; PTEN=phosphatase and tensin homolog; RAF1=v-raf-1 murine leukemia viral oncogene homolog 1; SLCO2B1=solute carrier organic anion transporter family, member 2B1; SLCO1B3=solute carrier organic anion transporter family, member 1B3; SNP=single nucleotide polymorphism; SPINK1=serine peptidase inhibitor, Kazal type 1; TMPRSS2-ERG=transmembrane protease, serine 2 v-ets erythroblastosis virus E26 oncogene homolog (avian).
European Urology  , DOI: ( /j.eururo )
Copyright © Terms and Conditions